Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium channel subfamily K member 13 (KCNK13), commonly known as THIK-1, is a two-pore domain potassium (K2P) channel that plays a pivotal role in the central nervous system (UniProt Q9HB14). It is the most abundant potassium channel expressed in microglia, where it is the primary regulator of the resting membrane potential (Madry et al., 2018). THIK-1 activity is essential for microglial surveillance, allowing these cells to constantly monitor the brain environment for damage or pathogens. Furthermore, this channel facilitates the release of interleukin-1 beta (IL-1β) through the NLRP3 inflammasome pathway, linking ion flux to inflammatory signaling (Izquierdo et al., 2021). Consequently, THIK-1 has emerged as a significant therapeutic target for neuroinflammatory and neurodegenerative conditions, such as Alzheimer's disease and stroke, where microglial dysfunction contributes to pathology. Pharmacological modulation, typically through inhibition by compounds like tetrapentylammonium or certain anesthetics, can suppress excessive microglial activation and pro-inflammatory signaling (Rajan et al., 2001). Targeting THIK-1 offers a unique opportunity to modulate the brain's innate immune response without directly affecting neuronal excitability, given its high enrichment in microglia.
THIK-1 functions as a background potassium leak channel that maintains the negative resting membrane potential of microglia; its inhibition leads to membrane depolarization, which impairs microglial motility and surveillance while also preventing the assembly of the NLRP3 inflammasome and subsequent IL-1β secretion (Madry et al., 2018; Izquierdo et al., 2021).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium channel subfamily K member 13 (THIK-1) (THIK-1).